Risk-Based Prophylactic Human Papillomavirus Vaccination of Heterosexual US Men Aged 27 to 45 Years for Prevention of Oropharyngeal Cancer
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag038 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Anil K Chaturvedi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Oropharyngeal Neoplasms, Vaccination. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: US National Cancer Institute, Cancer Prevention and Research Institute of Texas, NIH.
Abstract (Originalsprache)
Human papillomavirus (HPV) vaccination of US individuals aged 27–45 years is recommended through shared clinical decision-making. To enable shared decision-making, we used a microsimulation-based state-transition model to develop and validate a risk-prediction model to identify heterosexual men aged 27–45 years at high-risk of acquiring oral HPV-16 infections. A risk model for incident oral HPV-16 infections had good discrimination (AUC = 0.73) and calibration (ratio of expected to the observed number of incident oral HPV-16 infections through age 45 years [E/O] = 1.01) in internal cross-validation. Compared to vaccinating all men aged 27–45, vaccinating 44% of men with highest model-predicted risk would prevent 80% of incident oral HPV-16 infections through age 45 years and reduce the number needed to be vaccinated to prevent 1 infection by 45% (184 vs 100).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
- Information Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland, USA.
- Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Rebecca Landy
Förderung
- US National Cancer Institute
- Cancer Prevention and Research Institute of Texas
- NIH
Zitieren
APA
Chaturvedi, A. K., Haber, G. W., Graubard, B. I., Cheung, L. C., Gillison, M. L., & Landy, R. (2026). Risk-Based Prophylactic Human Papillomavirus Vaccination of Heterosexual US Men Aged 27 to 45 Years for Prevention of Oropharyngeal Cancer. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag038
Vancouver
Chaturvedi AK, Haber GW, Graubard BI, Cheung LC, Gillison ML, Landy R. Risk-Based Prophylactic Human Papillomavirus Vaccination of Heterosexual US Men Aged 27 to 45 Years for Prevention of Oropharyngeal Cancer. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag038
BibTeX
@article{Chaturvedi2026,
author = {Chaturvedi, Anil K and Haber, Gregory W and Graubard, Barry I and Cheung, Li C and Gillison, Maura L and Landy, Rebecca},
title = {Risk-Based Prophylactic Human Papillomavirus Vaccination of Heterosexual US Men Aged 27 to 45 Years for Prevention of Oropharyngeal Cancer},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag038}
}
EUVIMED